SG11202004005RA - Pharmaceutical compositions for controlling and/or reducing the progression of myopia - Google Patents

Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Info

Publication number
SG11202004005RA
SG11202004005RA SG11202004005RA SG11202004005RA SG11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA
Authority
SG
Singapore
Prior art keywords
myopia
progression
reducing
controlling
pharmaceutical compositions
Prior art date
Application number
SG11202004005RA
Other languages
English (en)
Inventor
Monica Jong
Padmaja Rajagopal Sankaridurg
Minas Theodore Coroneo
Iii Earl Leo Smith
Amandeep Kaur
Original Assignee
Brien Holden Vision Institute Ltd
Minas Theodore Coroneo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brien Holden Vision Institute Ltd, Minas Theodore Coroneo filed Critical Brien Holden Vision Institute Ltd
Publication of SG11202004005RA publication Critical patent/SG11202004005RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004005RA 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia SG11202004005RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581112P 2017-11-03 2017-11-03
PCT/AU2018/051187 WO2019084621A1 (fr) 2017-11-03 2018-11-02 Compositions pharmaceutiques pour lutter contre et/ou réduire la progression de la myopie

Publications (1)

Publication Number Publication Date
SG11202004005RA true SG11202004005RA (en) 2020-05-28

Family

ID=66331107

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004005RA SG11202004005RA (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Country Status (10)

Country Link
US (1) US20200345633A1 (fr)
EP (1) EP3703691A4 (fr)
JP (2) JP2021501803A (fr)
KR (1) KR20200088824A (fr)
CN (3) CN118403054A (fr)
AU (1) AU2018359013A1 (fr)
CA (1) CA3081593A1 (fr)
SG (1) SG11202004005RA (fr)
TW (1) TW201932104A (fr)
WO (1) WO2019084621A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (fr) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Détermination d'un changement d'une erreur de réfection d'un il
US20240261291A1 (en) * 2021-06-11 2024-08-08 Brien Holden Vision Institute Limited Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG61430B1 (bg) * 1994-03-23 1997-08-29 Иван ХРИСТОВ антиастматично лекарствено средство
WO1995033451A1 (fr) * 1994-06-06 1995-12-14 Warner-Lambert Company Medication pour traiter les allergies et les congestions des sinus sans effets sedatifs
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
WO2012161655A1 (fr) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition et/ou procédé pour réduire et/ou prévenir la progression de la myopie comprenant de l'atropine
JP5993620B2 (ja) * 2011-06-01 2016-09-14 ロート製薬株式会社 点眼剤
WO2016172712A2 (fr) * 2015-04-23 2016-10-27 Sydnexis, Inc. Composition ophtalmique

Also Published As

Publication number Publication date
CN111787920A (zh) 2020-10-16
JP2021501803A (ja) 2021-01-21
TW201932104A (zh) 2019-08-16
JP2023179418A (ja) 2023-12-19
WO2019084621A1 (fr) 2019-05-09
AU2018359013A1 (en) 2020-05-21
CN118403054A (zh) 2024-07-30
EP3703691A4 (fr) 2021-07-28
CA3081593A1 (fr) 2019-05-09
CN118384160A (zh) 2024-07-26
EP3703691A1 (fr) 2020-09-09
US20200345633A1 (en) 2020-11-05
KR20200088824A (ko) 2020-07-23

Similar Documents

Publication Publication Date Title
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
IL271807A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
IL261444A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
EP3558279A4 (fr) Compositions et méthode s pour le traitement d'une douleur chronique
EP3720421A4 (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3651801A4 (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3429584A4 (fr) Compositions et méthodes de traitement de la presbytie
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
EP3303366A4 (fr) Dérivés de dolastatine 10 et utilisations de ceux-ci
IL272121A (en) Preparation and methods for the treatment of myopia
EP3426671A4 (fr) Composés et compositions pour le traitement d'infections
IL269400A (en) Medicines and preparations for the treatment of eye disorders
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
EP3341006A4 (fr) Compositions et méthodes pour le traitement d'une lésion neurologique
EP3706767A4 (fr) Compositions et méthodes pour le traitement d'une allergie
SG11202004005RA (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
EP3518951A4 (fr) Compositions et méthodes pour le traitement d'affections orthopédiques
EP3568020A4 (fr) Compositions et méthodes pour le traitement d'états démyélinisants
IL265242B (en) Compounds for the treatment of hypertension and/or fibrosis
EP3534924A4 (fr) Composition pour la prévention et/ou le traitement de maladies cardiovasculaires
EP3525787A4 (fr) Méthodes de traitement et compositions pharmaceutiques utilisant bcn057 ou bcn512